Pharmacokinetics of oral timolol studied by mass fragmentography
- 1 February 1981
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 19 (3) , 193-196
- https://doi.org/10.1007/bf00561948
Abstract
The pharmacokinetics of timolol, after oral administration of single 20 mg doses to healthy subjects, has been studied using an original electron beam ionization GLC-mass spectrometry technique with computer — controlled multiple ion detection. This method of mass fragmentography, tested with propranolol as an internal standard, permitted the measurement of timolol concentrations as low as 1 ng/ml with good precision and accuracy. It enabled the plasma level to be followed up to the twelfth hour after treatment. Individual variation was observed in bioavailability; the peaks plasma concentration (Cmax) of 50 to 103 ng/ml being achieved at different times(0.5–3 h). The residual level after 12 h differed greatly between the subjects (0.8 to 7.2 ng/ml). The mean half-life of the terminal elimination phase was 2.62 ± 0.17 h. Extra-renal elimination (metabolic and biliary) represented the main route of elimination, with a renal to body clearance ratio of 0.123. This level paralleled the percentage of unaltered timolol excreted in urine 24 h after its administration.This publication has 8 references indexed in Scilit:
- The disposition of timolol in manJournal of Pharmacy and Pharmacology, 1978
- IGPHARM: Interactive graphic package for pharmacokinetic analysisComputers and Biomedical Research, 1978
- Timolol kinetics in chronic renal insufficiencyClinical Pharmacology & Therapeutics, 1978
- Plasma timolol levels after oral and intravenous administrationEuropean Journal of Clinical Pharmacology, 1978
- Acebutolol metabolite plasma concentration during chronic oral therapy.British Journal of Clinical Pharmacology, 1977
- Clinical pharmacokinetics of atenolol.1977
- Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66,082), a new cardioselective beta‐adrenoceptor blocking drug.British Journal of Clinical Pharmacology, 1976
- PHYSIOLOGICAL DISPOSITION AND METABOLISM OF TIMOLOL IN MAN AND LABORATORY-ANIMALS1975